Table 5.
Odds ratios (ORs) and 95% confidence intervals (CIs) of clinical status and HMGB1 rs1360485 genotypic frequencies in 579 patients with prostate cancer.
| Variable | Genotypic Frequencies | |||
|---|---|---|---|---|
| rs1360485 | TT (N = 347) | TC + CC (N = 232) | OR (95% CI) | p-Value |
| PSA at diagnosis (ng/mL) | ||||
| ≤10 | 161 (46.4%) | 109 (47.0%) | 1.00 | p = 0.890 |
| >10 | 186 (53.6%) | 123 (53.0%) | 0.977 (0.700–1.363) | |
| Pathologic Gleason grade group | ||||
| 1 + 2 + 3 | 299 (86.2%) | 185 (79.7%) | 1.00 | p = 0.041 * |
| 4 + 5 | 48 (13.8%) | 47 (20.3%) | 1.583 (1.017–2.462) | |
| Clinical T stage | ||||
| 1 + 2 | 302 (87.0%) | 199 (85.8%) | 1.00 | p = 0.664 |
| 3 + 4 | 45 (13.0%) | 33 (14.2%) | 1.113 (0.686–1.805) | |
| Pathologic T stage | ||||
| 2 | 197 (56.8%) | 109 (47.0%) | 1.00 | p = 0.021 * |
| 3 + 4 | 150 (43.2%) | 123 (53.0%) | 1.482 (1.061–2.070) | |
| Pathologic N stage | ||||
| N0 | 326 (93.9%) | 204 (87.9%) | 1.00 | p = 0.011 * |
| N1 | 21 (6.1%) | 28 (12.1%) | 2.131 (1.178–3.852) | |
| Seminal vesicle invasion | ||||
| No | 279 (80.4%) | 173 (74.6%) | 1.00 | p = 0.096 |
| Yes | 68 (19.6%) | 59 (25.4%) | 1.399 (0.941–2.081) | |
| Perineural invasion | ||||
| No | 97 (28.0%) | 58 (25.0%) | 1.00 | p = 0.431 |
| Yes | 250 (72.0%) | 174 (75.0%) | 1.164 (0.797–1.700) | |
| Lymphovascular invasion | ||||
| No | 296 (85.3%) | 186 (80.2%) | 1.00 | p = 0.105 |
| Yes | 51 (14.7%) | 46 (19.8%) | 1.435 (0.926–2.226) | |
| D’Amico classification | ||||
| Low/Intermediate risk | 178 (51.3%) | 102 (44.0%) | 1.00 | p = 0.084 |
| High risk | 169 (48.7%) | 130 (56.0%) | 1.342 (0.961–1.875) | |
The ORs and their 95% CIs were estimated by logistic regression models. * p-value < 0.05 = statistically significant.